Coligo Medical

What Coligo Medical does

Coligo Medical is a South Africa-based specialty medical device distributor founded in October 2020 (headquartered in Cape Town per website and contact phone number 021 300 7809; firmographics list Johannesburg), serving hospitals, transplant centers, and wound care centers with niche, technologically advanced imported devices. The company holds exclusive South African distribution rights for four international principals: Glycorex Transplantation (Glycosorb ABO and Glycosorb ABO 4ml molecular-level antibody-removal devices that enable blood group incompatible organ transplantation), XVIVO (organ perfusion systems including Kidney Assist Transport, Kidney Assist, Liver Assist, and XPS ex-vivo lung perfusion, plus PERFADEX Plus preservation solution), Carnamedica (organ procurement and preservation consumables including PlegiStore HTK solution and PumpProtect perfusion solution), and Plasmacure (PLASOMA cold plasma wound therapy for chronic and post-surgical ulcers).

The product portfolio addresses the full transplant workflow — from organ preservation and ex-vivo perfusion through transport to blood-group-barrier-crossing transplantation — and extends into advanced wound care via cold plasma technology. Underlying technologies include hypothermic and normothermic machine perfusion, pressure-controlled centrifugal pumps with hollow fiber oxygenators, EVLP platforms, HTK-based cardioplegia-style preservation chemistry, and molecular antibody specificity columns. Glycosorb ABO is documented in over 60 scientific articles and over 6,000 transplants globally; Liver Assist is documented in more than 100 peer-reviewed publications and five randomized control trials; PLASOMA is reported as 2.5x more effective than standard of care in chronic wound healing.

Coligo generates revenue through hardware sales and consumable distribution to healthcare institutions in South Africa, operating a direct sales model with quote-based pricing tied to public-sector procurement. The go-to-market emphasizes personalized service, professional training, and implementation support, anchored by a flagship collaboration with Groote Schuur Hospital, where the company supported the first blood group incompatible kidney transplant on the African continent in February 2023 using Glycosorb ABO technology. The firm has 1-10 employees, no disclosed funding, and operates exclusively in the South African market.

Name

Coligo Medical

Legal name

Coligo Medical

Website

https://coligomedical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Coligo Medical is a South African medical device distributor founded in 2020 that supplies niche transplant and wound care technologies to hospitals and transplant centers, representing Glycorex, XVIVO, Carnamedica, and Plasmacure.

Ownership category

akta.pro rank

Headquarters

HQ city

Johannesburg

HQ country

South Africa

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Distribution: Coligo Medical generates revenue by distributing niche and technologically advanced medical devices in South Africa, operating as the South African distributor for multiple international medical technology partners including Glycorex Transplantation, XVIVO, Carnamedica, and Plasmacure. The company offers products for organ transplantation and wound care, selling to healthcare institutions and transplant centers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Coligo Medical is a South African specialty distributor of niche, technologically advanced medical devices for thoracic, abdominal, and transplant procedures, as well as advanced wound care. The company is the South African distributor for four international technology partners (XVIVO, Glycorex Transplantation, Carnamedica, and Plasmacure), offering organ perfusion systems, blood group incompatible transplant solutions, organ preservation fluids, and cold plasma wound therapy to hospitals and transplant centers.

Product overview

Coligo Medical is a South African medical device distributor established in October 2020, offering niche and technologically advanced medical devices focused on organ transplantation and wound care. The company's product portfolio comprises four core product brands: XVIVO (organ perfusion and preservation solutions including Kidney Assist, Liver Assist, XPS, and PERFADEX Plus), Glycorex (blood optimization technology including Glycosorb ABO for blood group incompatible transplants), Carnamedica (organ procurement and preservation solutions including PlegiStore and PumpProtect), and Plasmacure (cold plasma wound therapy with PLASOMA). These products work together to address the full spectrum of transplant medicine from organ preservation through compatible transplantation and chronic wound treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• XVIVO Organ Perfusion and Preservation Systems Advanced organ preservation and perfusion devices for kidney, liver, and lung transplantation, including hypothermic machine perfusion transport systems, temperature-controlled perfusion systems (12-37°C), ex-vivo lung perfusion platforms with integrated disposable kits, and ready-to-use lung preservation solutions. Sold to transplant centers and hospitals in South Africa.
• Glycosorb ABO Medical device that uses molecular-level technology to specifically select and remove anti-A/B antibodies from blood, enabling organ transplants across the blood group barrier. Used in kidney, stem cell, liver, heart, and lung transplants; over 6,000 transplants performed globally with documented short- and long-term safety. Sold to hospitals and transplant centers.
• Glycosorb ABO 4ml Variant of Glycosorb ABO designed for specific reduction of anti-A/B antibodies in blood plasma without significantly affecting other antibodies or vital blood components, facilitating transfusions to patients regardless of blood group. Sold to blood banks and transfusion services.
• Carnamedica Organ Preservation Solutions Organ procurement and preservation solutions developed through 14 years of collaboration with Polish transplant surgeons, including Histidine-Tryptophan-Ketoglutarate (HTK) cardioplegia/perfusion solution and sterile perfusion solution for in-vitro flushing and temporary continuous perfusion preservation of explanted organs. Sold to transplant surgical teams.
• PLASOMA Cold Plasma Wound Therapy Cold plasma wound therapy system consisting of a flexible cold plasma pad and pulser for advanced wound care, including diabetic foot ulcers, leg ulcers, pressure ulcers, burn wounds, and post-surgical ulcers. The device automatically tracks treatment and stops if irregularities are detected; clinical results indicate 2.5x more effective than standard of care. Sold to wound care centers and hospitals.

Quantifiable outcome

• Clinical results indicate PLASOMA treatment is 2.5x more effective than Standard of Care for wound healing
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Glycorex Transplantation ABcoreTechnology or Integration · 20 February 2023Coligo Medical is the South African distributor for Glycorex Transplantation AB, a Swedish company that developed Glycosorb® ABO, a medical device enabling organ transplants across the blood group barrier. Glycorex has developed molecular-level technology that specifically selects and removes antibodies in blood. The partnership enabled the first blood group incompatible kidney transplant in South Africa and on the African continent at Groote Schuur Hospital in February 2023.
• XVIVOcoreTechnology or IntegrationColigo Medical distributes XVIVO's advanced organ preservation technology including Kidney Assist Transport™, Kidney Assist™, Liver Assist™, XPS™ lung perfusion platform, and PERFADEX® Plus. XVIVO is a trusted provider of organ preservation solutions enabling clinicians worldwide to preserve, transport, and assess organs outside the body.
• CarnamedicacoreTechnology or IntegrationColigo Medical distributes Carnamedica's organ procurement and preservation solutions including PlegiStore® (HTK solution) and PumpProtect® perfusion solution. Carnamedica has 14 years of close collaboration with Polish transplant surgeons developing surgical devices for daily clinical practice in transplant surgery.
• PlasmacurecoreTechnology or IntegrationColigo Medical distributes Plasmacure's PLASOMA cold plasma technology for wound treatment. Plasmacure has developed a safe way to apply cold plasma directly in wounds for advanced wound care including diabetic foot ulcers, leg ulcers, pressure ulcers, burn wounds, and post-surgical ulcers.
• Groote Schuur HospitalflagshipStrategic or Co-development PartnerColigo Medical collaborates with Groote Schuur Hospital's transplant team, providing Glycosorb® ABO for blood group incompatible kidney transplants. This partnership achieved the historic first blood group incompatible kidney transplant on the African continent in February 2023. The hospital is a key reference site and collaborative partner for advancing transplant technology in South Africa.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• ConvaTec: Global medical products company specializing in advanced wound care, ostomy, and continence care with distribution across multiple markets. Comparable as a broad incumbent in the advanced wound care space that Coligo's PLASOMA addresses.
• Mölnlycke Health Care: Global wound care and surgical solutions company with significant presence in advanced wound care dressings and single-use surgical products. Comparable as a broad incumbent in the chronic wound care vertical where Coligo's PLASOMA competes.
• B. Braun (Africa operations): Global medical device and pharmaceutical company with a South African subsidiary distributing hospital products including infusion, surgical, and wound care solutions. Comparable as a broad incumbent in the same hospital distribution channel.
• Smith & Nephew (Africa): Global medical device company with a strong wound care portfolio (including advanced wound dressings and negative pressure wound therapy) and Africa presence. Comparable as a broad incumbent that competes with Coligo's PLASOMA wound care line.
• Teleflex (Africa operations): Global medical device company with established Africa distribution serving hospitals with surgical and critical care products. Comparable as a larger incumbent medical device distributor that could compete with or absorb Coligo's role in specific product lines.

Direct peers

• Adcock Ingram Critical Care: South African healthcare company with a critical care division distributing medical devices and consumables to hospitals. Comparable as a domestic medical device distributor serving the same hospital procurement channel.
• Ascendis Medical: South African specialty medical device distributor focused on niche and technologically advanced medical devices across multiple therapeutic areas. Directly comparable to Coligo as a domestic specialty distribution peer serving hospitals with imported, high-value medtech.
• Litha Healthcare Group: South African healthcare company distributing medical devices and pharmaceuticals to hospitals and clinics. Comparable as a domestic specialty medical device distributor operating in the same South African hospital channel.

Others

• XVIVO: Swedish organ preservation and perfusion technology company whose products (Kidney Assist, Liver Assist, XPS, PERFADEX Plus) Coligo distributes in South Africa. Comparable as a technology principal/ecosystem partner; relevant because the relationship terms directly drive Coligo's revenue.
• Glycorex Transplantation AB: Swedish medtech company that developed Glycosorb ABO, the antibody removal device enabling blood group incompatible transplants, distributed by Coligo in South Africa. Comparable as a technology principal whose distribution arrangement is core to Coligo's transplant business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/coligo-medical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coligo Medical